Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Allegheny Financial Group

Allegheny Financial Group decreased its position in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 54.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,725 shares of the biopharmaceutical company's stock after selling 10,386 shares during the quarter. Allegheny Financial Group's holdings in Bristol-Myers Squibb were worth $494,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Keel Point LLC grew its position in Bristol-Myers Squibb by 12.8% in the fourth quarter. Keel Point LLC now owns 5,648 shares of the biopharmaceutical company's stock worth $319,000 after acquiring an additional 642 shares in the last quarter. Westbourne Investments Inc. bought a new stake in Bristol-Myers Squibb in the fourth quarter worth $726,000. Freestone Grove Partners LP purchased a new position in Bristol-Myers Squibb during the fourth quarter worth $875,000. Widmann Financial Services Inc. boosted its stake in shares of Bristol-Myers Squibb by 4.9% during the 4th quarter. Widmann Financial Services Inc. now owns 7,956 shares of the biopharmaceutical company's stock worth $450,000 after purchasing an additional 370 shares during the period. Finally, Parvin Asset Management LLC bought a new stake in Bristol-Myers Squibb in the fourth quarter worth about $419,000. 76.41% of the stock is currently owned by institutional investors.

Bristol-Myers Squibb Stock Down 1.0 %

Shares of BMY traded down $0.52 during mid-day trading on Monday, hitting $50.05. 11,343,391 shares of the company traded hands, compared to its average volume of 12,968,118. The company has a market capitalization of $101.86 billion, a PE ratio of -11.32, a price-to-earnings-growth ratio of 2.07 and a beta of 0.41. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year high of $63.33. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90. The business has a 50 day moving average of $55.68 and a 200 day moving average of $56.41.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping the consensus estimate of $1.50 by $0.30. The business had revenue of $11.20 billion during the quarter, compared to the consensus estimate of $10.77 billion. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The business's revenue for the quarter was down 5.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($4.40) earnings per share. Equities research analysts anticipate that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, May 1st. Shareholders of record on Friday, April 4th were issued a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 4.96%. The ex-dividend date was Friday, April 4th. Bristol-Myers Squibb's payout ratio is 92.88%.

Analysts Set New Price Targets

BMY has been the subject of a number of recent analyst reports. Citigroup boosted their price objective on Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a "neutral" rating in a report on Tuesday, January 28th. Truist Financial raised their target price on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th. Cantor Fitzgerald reiterated a "neutral" rating and issued a $55.00 price target on shares of Bristol-Myers Squibb in a report on Tuesday, April 22nd. Jefferies Financial Group decreased their target price on Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a research report on Wednesday, April 23rd. Finally, Argus raised Bristol-Myers Squibb to a "hold" rating in a research report on Friday, April 25th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have assigned a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $58.00.

Insider Buying and Selling at Bristol-Myers Squibb

In related news, EVP Samit Hirawat purchased 4,250 shares of Bristol-Myers Squibb stock in a transaction that occurred on Friday, April 25th. The stock was bought at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the transaction, the executive vice president now owns 83,513 shares in the company, valued at $3,973,548.54. The trade was a 5.36 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.